Pancreatic cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Patients have good compliance, can understand the study process, and signed the written informed consent; (2) age =18 years old and =70 years old; (3) patients with a histopathological or cytological diagnosis of pancreatic ductal adenocarcinoma, or a clinical diagnosis of pancreatic ductal adenocarcinoma Of the patients; (4) ECOG=1; (5) predicted survival time=3 months; (6) expected radical resection of the tumor; (7) no distant metastasis; (8) no history of neoadjuvant chemoradiotherapy; (9) There were no serious systemic complications.
Exclusion criteria
Exclusion criteria: (1) patients with other malignant tumors or received antitumor therapy in the past 5 years; (2) non-pancreatic ductal adenocarcinoma confirmed by postoperative pathology; (3) patients unable to receive chemotherapy due to postoperative complications or poor physical status; (4) patients of childbearing age who are pregnant or lactating or who refuse to use appropriate contraception during the course of the trial; (5) having participated in other trial investigators within 30 days; (6) patients with failure of organoid model construction or failure of drug screening experiments due to various reasons; (7)Patients who were deemed by the investigator to be ineligible for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One-year survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival;Overall survival; | — |
Countries
China
Contacts
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College